Hims & Hers Health (NYSE:HIMS) experienced a notable surge in stock value, increasing by over 8% to approximately $26. This rise follows the announcement from the U.S. Food and Drug Administration (FDA) regarding its review of certain wellness peptides used in compounding pharmacies.
FDA Review of Peptide Compounds
On July 23 and 24, the FDA is set to convene its Pharmacy Compounding Advisory Committee. This meeting aims to evaluate whether specific bulk drug substances related to peptides should be added to the 503A bulks list.
Peptides Under Review
- BPC-157
- KPV
- TB-500
- MOTs-C
- Emideltide
- Semax
- Epitalon
In preparation for these discussions, the FDA has opened a public comment period, with submissions due in early July. The outcomes of these meetings could potentially reshape the regulatory landscape for peptide compounds.
Market Reactions
Following the FDA’s announcement, Bank of America upgraded its price target for Hims & Hers Health from $21 to $25. The bank maintained a ‘Neutral’ rating, citing an upward trend in peer valuations and the promising nature of peptide-related developments.
Analyst Insights
Bank of America analysts raised their target valuation multiples from approximately 21.5x to 25.5x. They view the FDA’s review as a constructive move for long-term potential, though it is not expected to influence earnings in the short term.
The review could open avenues for new compounding possibilities and broaden demand for wellness peptides. However, uncertainty prevails regarding whether these substances will be allowed for compounding or wider commercialization.
Strategic Implications for Hims & Hers
While current restrictions remain unchanged, this review adds strategic options for companies involved in compounding. For Hims & Hers, favorable future rulings may allow the company to reallocate resources from GLP-1-related operations to develop peptide-based products.
This shift could help mitigate fixed operating costs while capitalizing on new market opportunities, depending on the FDA’s final decisions. As the review unfolds, the biotech and wellness sectors will closely monitor these developments.
